MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer

Neven, Patrick; Johnston, Stephen R. D.; Toi, Masakazu; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; Kaufman, Peter A.; Koh, Han; Grischke, Eva-Maria; Conte, PierFranco; Lu, Yi; Haddad, Nadine; Hurt, Karla C.; Llombart-Cussac, Antonio; Sledge, George W.

dc.contributor.author	Grischke, Eva-Maria
dc.date.accessioned	2022-07-12T10:06:36Z
dc.date.available	2022-07-12T10:06:36Z
dc.date.issued	2021
dc.identifier.issn	1078-0432
dc.identifier.uri	http://hdl.handle.net/10900/129349
dc.language.iso	en	de_DE
dc.publisher	Philadelphia	de_DE
dc.relation.uri	http://dx.doi.org/10.1158/1078-0432.CCR-20-4685	de_DE
dc.subject.ddc	610	de_DE
dc.title	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer	de_DE
dc.type	Article	de_DE
utue.quellen.id	20220404000000_00736
utue.publikation.seiten	5801-5809	de_DE
utue.personen.roh	Neven, Patrick
utue.personen.roh	Johnston, Stephen R. D.
utue.personen.roh	Toi, Masakazu
utue.personen.roh	Sohn, Joohyuk
utue.personen.roh	Inoue, Kenichi
utue.personen.roh	Pivot, Xavier
utue.personen.roh	Burdaeva, Olga
utue.personen.roh	Okera, Meena
utue.personen.roh	Masuda, Norikazu
utue.personen.roh	Kaufman, Peter A.
utue.personen.roh	Koh, Han
utue.personen.roh	Grischke, Eva-Maria
utue.personen.roh	Conte, PierFranco
utue.personen.roh	Lu, Yi
utue.personen.roh	Haddad, Nadine
utue.personen.roh	Hurt, Karla C.
utue.personen.roh	Llombart-Cussac, Antonio
utue.personen.roh	Sledge, George W.
dcterms.isPartOf.ZSTitelID	Clinical Cancer Research	de_DE
dcterms.isPartOf.ZS-Issue	21	de_DE
dcterms.isPartOf.ZS-Volume	27	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE